Curie company Curis, Inc. (NASDAQ: CRIS) was founded in 2000 and is headquartered in Lexington, Massachusetts, USA, with 55 full-time employees. It is a biotechnology company engaged in the research and development of human cancer treatment drugs.
Curis, Inc. is a biopharmaceutical company engaged in the research and development of cancer, neurological and dermatological drugs, with controllable tissue and organ repair and regeneration products.
Curie Curis (CRIS) company products:
- CUDC-907-an oral histone deacetylase and phosphatidylinositol-3-kinase inhibitor, currently in the treatment of lymphoma, multiple myeloma, HER 2-/ ER+ or PR+ breast cancer and NUT midline cancer Clinical trial stage;
- CUDC-427 —— currently in the phase I clinical trials for advanced solid tumors and lymphomas; at the same time in the preclinical trials for cancer programmed death ligand antagonists; in the leukemia preclinical trials;
- CUDC-305-in the clinical trial stage for systemic mastocytosis disease and glioblastoma;
- Erivedge-an oral small molecule hedgehog pathway inhibitor for the treatment of advanced basal cell carcinoma (BCC); in addition, Erivedge is still in the phase II clinical trials of multiple BCC and idiopathic pulmonary fibrosis treatments.
In addition, Curie and Aurigene Discovery Technologies Limited are cooperating to develop, develop and commercialize the application of small molecule compounds in the fields of immuno-oncology and oncology, and cooperate with Roche (F. Hoffmann-La Roche Ltd.) and Genentech. The company (Genentech Inc.) jointly developed and commercialized Erivedge.